Top Health-care stocks: <\/p>\n
JNJ: -0.1% <\/p>\n
PFE: -0.3% <\/p>\n
ABT: flat <\/p>\n
MRK: flat <\/p>\n
AMGN: flat <\/p>\n
Health-care shares were generally unchanged in pre-market trade Monday. <\/p>\n
In health-care stocks news, Shares of Neothetics Inc. ( NEOT ) gained pre-market Monday after the company said it is commencing two pivotal Phase 3 trials to determine the efficacy, safety and tolerability of LIPO-202 for reducing central abdominal bulging. The specialty pharmaceutical firm said the two trials will be conducted in approximately 80 sites across the U.S and enroll a total of 1,600 patients. <\/p>\n
Shares in the company were trading 1.2% higher at $8.25 during pre-market trading . Over the past 52 weeks, the company has traded between $6.11 and $14.10. <\/p>\n
AEterna Zentaris ( AEZS ) said Monday it plans to conduct a phase 3 clinical study to demonstrate the efficacy of Macrilen (macimorelin), an orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency ( AGHD ). The study will also evaluate the effects of Macrilen on myocardial repolarization. <\/p>\n
<\/p>\n
View post: <\/p>\n
Health Care Sector Update for 04\/13\/2015: NEOT, AEZS, REPH<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Top Health-care stocks: JNJ: -0.1% PFE: -0.3% ABT: flat MRK: flat AMGN: flat Health-care shares were generally unchanged in pre-market trade Monday. In health-care stocks news, Shares of Neothetics Inc. ( NEOT ) gained pre-market Monday after the company said it is commencing two pivotal Phase 3 trials to determine the efficacy, safety and tolerability of LIPO-202 for reducing central abdominal bulging. Continue reading